Physician profile
Sanjeeb Shrestha
NPI 1356384473
$2,933.24
in general payments reported to CMS, 2019-2025
27 companies · $977 in 2025
The $977 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.23 · 2020: $31.86 · 2021: $153 · 2022: $446 · 2023: $499 · 2024: $748 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.10 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,235.17 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $472.38 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $200.95 | 2022-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $111.48 | 2022-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $102.38 | 2025 | Voquezna |
| Ardelyx, INC. | $93.20 | 2023-2025 | Ibsrela |
| Celgene Corporation | $93.06 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $84.37 | 2024-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $69.33 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $64.98 | 2019-2024 | |
| Medtronic, INC. | $46.68 | 2024 | Ligasure |
| Shionogi INC | $45.11 | 2019-2020 | |
| Madrigal Pharmaceuticals | $41.58 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $36.42 | 2023 | Sutab, Suflave |
| Boston Scientific Corporation | $29.43 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $28.96 | 2025 | |
| Lilly USA, LLC | $24.56 | 2024 | Omvoh |
| Novo Nordisk INC | $21.35 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $20.30 | 2022 | |
| Echosens North America, INC. | $17.89 | 2025 | Fibroscan |
| Celltrion USA INC. | $17.38 | 2024 | Vegzelma |
| Stryker Corporation | $17.34 | 2023 | Neptune |
| Fresenius Kabi USA, LLC | $15.70 | 2024 | Idacio |
| Evoke Pharma, INC. | $15.15 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.31 | 2019 | |
| Daiichi Sankyo INC. | $13.78 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeeb Shrestha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.